support@nanobiousa.com

1-888-678-8889 (USA)

LOGIN

Nanobio Delivery Pharmaceutical Co., Ltd has been dissolved at 12/31/2019. The website is as the previous business records only. If you have any needs, please email: hhu@nanobiousa.com

Home > PRODUCTS & SERVICES > RNA Nanoparticles > Catalogue number >

RNA Nanoparticles for Targeting Study: Get Quote

Product Name Size Catalog No.
3WJ-RFA(TNBC)-FL

Near Infrared labeled serum stable 3WJ RNA Nanoparticle with an aptamer targeting  Triple Negative Breast Cancer (TNBC) cells

 1nmol RNP-F01-1
50nmol RNP-F01-2
3WJ-RFA(PC)-FL

Near Infrared labeled serum stable 3WJ RNA Nanoparticle with an aptamer targeting Prostate Cancer (PC) cells

 1nmol RNP-F02-1
50nmol RNP-F02-2
3WJ-RFA(HER2)-FL

Near Infrared labeled serum stable 3WJ RNA Nanoparticle with an aptamer targeting HER2 + cancer cells

 1nmol RNP-F03-1
50nmol RNP-F03-1
3WJ-RFA(EC)-FL

Near Infrared labeled serum stable 3WJ RNA Nanoparticle with an aptamer targeting Epithelial Cancer (EC) cells

 1nmol RNP-F04-1
50nmol RNP-F04-2
3WJ-RFC(FA)-FL

Near Infrared labeled serum stable 3WJ RNA Nanoparticle with a folate ligand for targeting folate receptor (+) cells

 1nmol RNP-F05-1
50nmol RNP-F05-2
3WJ-RFC(GL)-FL

Near Infrared labeled serum stable 3WJ RNA Nanoparticle with a galactose ligand for targeting liver cancer cells

 1nmol RNP-F06-1
50nmol RNP-F06-2
3WJ-RFM-FL

Near Infrared labeled serum stable 3WJ RNA Nanoparticle with a mutant aptamer (serving as  a targeting control)

 1nmol RNP-F07-1
50nmol RNP-F07-2
3WJ-RF-FL

Near Infrared labeled serum stable 3WJ RNA Nanoparticle without ligand (serving as vector control)

 1nmol RNP-F08-1
50nmol RNP-F08-2

RNA Nanoparticles for miRNA17 Delivery Study: Get Quote

Product Name Size Catalog No.
3WJ-RFA(TNBC)-antiMIR17

Serum stable 3WJ RNA Nanoparticle with an aptamer targeting Triple Negative Breast Cancer ( TNBC) cells and antiMIR17

 1nmol RNP-M17-01-1
50nmol RNP-M17-01-2
3WJ-RFA(PC)-antiMIR17

Serum stable 3WJ RNA Nanoparticle with an aptamer targeting Prostate Cancer (PC ) cells and antiMIR17

 1nmol RNP-M17-02-1
50nmol RNP-M17-02-2
3WJ-RFA(HER2)-antiMIR17

Serum stable 3WJ RNA Nanoparticle with an aptamer targeting HER2 + cancer cells and antiMIR17

 1nmol RNP-M17-03-1
50nmol RNP-M17-03-2
3WJ-RFA(EC)-antiMIR17

Serum stable 3WJ RNA Nanoparticle with an aptamer targeting Epithelial Cancer (EC) cells and antiMIR17

 1nmol RNP-M17-04-1
50nmol RNP-M17-04-2
3WJ-RFC(FA)-antiMIR17

Serum stable 3WJ RNA Nanoparticle with a folate ligand for targeting folate receptor (+) cells and antiMIR17

 1nmol RNP-M17-05-1
50nmol RNP-M17-05-2
3WJ-RFC(GL)-antiMIR17

Serum stable 3WJ RNA Nanoparticle with a galactose ligand for targeting liver cancer cells and antiMIR17

 1nmol RNP-M17-06-1
50nmol RNP-M17-06-2
3WJ-RFM-antiMIR17

Serum stable 3WJ RNA Nanoparticle with a mutant aptamer (serving as a targeting control) and antiMIR17

 1nmol RNP-M17-07-1
50nmol RNP-M17-07-2
3WJ-RF-antiMIR17

Serum stable 3WJ RNA Nanoparticle without ligand (serving as vector control) an but with antiMIR17

 1nmol RNP-M17-08-1
50nmol RNP-M17-08-2

RNA Nanoparticles for miRNA19 Delivery Study: Get Quote

Product Name Size Catalog No.
3WJ-RFA(TNBC)-antiMIR19

Serum stable 3WJ RNA Nanoparticle with an aptamer targeting  Triple Negative Breast Cancer (TNBC) cells and antiMIR19

 1nmol RNP-M19-01-1
50nmol RNP-M19-01-2
3WJ-RFA(PC)-antiMIR19

Serum stable 3WJ RNA Nanoparticle with an aptamer targeting Prostate Cancer (PC) cells and antiMIR19

 1nmol RNP-M19-02-1
50nmol RRNP-M19-02-2
3WJ-RFA(HER2)-antiMIR19

Serum stable 3WJ RNA Nanoparticle with an aptamer targeting HER2 + cancer cells and antiMIR19

 1nmol RNP-M19-03-1
50nmol RNP-M19-03-2
3WJ-RFA(EC)-antiMIR19

Serum stable 3WJ RNA Nanoparticle with an aptamer targeting Epithelial Cancer (EC) cells and antiMIR19

 1nmol RNP-M19-04-1
50nmol RNP-M19-04-2
3WJ-RFC(FA)-antiMIR19

Serum stable 3WJ RNA Nanoparticle with a folate ligand for targeting folate receptor (+) cells and antiMIR19

 1nmol RNP-M19-05-1
50nmol RNP-M19-05-2
3WJ-RFC(GL)-antiMIR19

Serum stable 3WJ RNA Nanoparticle with a galactose ligand for targeting liver cancer cells and antiMIR19

 1nmol RNP-M19-06-1
50nmol RNP-M19-06-2
3WJ-RFM-antiMIR19

Serum stable 3WJ RNA Nanoparticle with a mutant aptamer (serving as a targeting control) and antiMIR19

 1nmol RNP-M19-07-1
50nmol RNP-M19-07-2
3WJ-RF-antiMIR19

Serum stable 3WJ RNA Nanoparticle without ligand (serving as vector control) but with antiMIR19

 1nmol RNP-M19-08-1
50nmol RNP-M19-08-2

RNA Nanoparticles for miRNA21 Delivery Study: Get Quote

Product Name Size Catalog No.
3WJ-RFA(TNBC)-antiMIR21

Serum stable 3WJ RNA Nanoparticle with an aptamer targeting Triple Negative Breast Cancer (TNBC) cells and antiMIR21

 1nmol RNP-M21-01-1
50nmol RNP-M21-01-2
3WJ-RFA(PC)-antiMIR21

Serum stable 3WJ RNA Nanoparticle with an aptamer targeting Prostate Cancer (PC) cells and antiMIR21

 1nmol RNP-M21-02-1
50nmol RNP-M21-02-2
3WJ-RFA(HER2)-antiMIR21

Serum stable 3WJ RNA Nanoparticle with an aptamer targeting HER2 + cancer cells and antiMIR21

 1nmol RNP-M21-03-1
50nmol RNP-M21-03-2
3WJ-RFA(EC)-antiMIR21

Serum stable 3WJ RNA Nanoparticle with an aptamer targeting Epithelial Cancer (EC) cells and antiMIR21

 1nmol RNP-M21-04-1
50nmol RNP-M21-04-2
3WJ-RFC(FA)-antiMIR21

Serum stable 3WJ RNA Nanoparticle with a folate ligand for targeting folate receptor (+) cells and antiMIR21

 1nmol RNP-M21-05-1
50nmol RNP-M21-05-2
3WJ-RFC(GL)-antiMIR21

Serum stable 3WJ RNA Nanoparticle with a galactose ligand for targeting liver cancer cells and antiMIR21

 1nmol RNP-M21-06-1
50nmol RNP-M21-06-2
3WJ-RFM-antiMIR21

Serum stable 3WJ RNA Nanoparticle with a mutant aptamer (serving as a targeting control) and antiMIR21

 1nmol RNP-M21-07-1
50nmol RNP-M21-07-02
3WJ-RF-antiMIR21

Serum stable 3WJ RNA Nanoparticle without ligand (serving as vector control) but with antiMIR21

 1nmol RNP-M21-08-01
50nmol RNP-M21-08-02

RNA Nanoparticles for miRNA Delivery Study, scramble controls: Get Quote

Product Name Size Catalog No.
3WJ-RFA(TNBC)-Scr

Serum stable 3WJ RNA Nanoparticle with an aptamer targeting Triple Negative Breast Cancer (TNBC) cells and scramble miRNA

 1nmol RNP-Msc-01-1
50nmol RNP-Msc-01-2
3WJ-RFA(PC)-Scr

Serum stable 3WJ RNA Nanoparticle with an aptamer targeting Prostate Cancer (PC) cells and scramble miRNA

 1nmol RNP-Msc-02-1
50nmol RNP-Msc-02-2
3WJ-RFA(HER2)-Scr

SSerum stable 3WJ RNA Nanoparticle with an aptamer targeting  HER2 + cancer cells and scramble miRNA

 1nmol RNP-Msc-03-1
50nmol RNP-Msc-03-2
3WJ-RFA(EC)-Scr

Serum stable 3WJ RNA Nanoparticle with an aptamer targeting Epithelial Cancer (EC) cells and scramble miRNA

 1nmol RNP-Msc-04-1
50nmol RNP-Msc-04-2
3WJ-RFC(FA)-Scr

Serum stable 3WJ RNA Nanoparticle with a folate ligand for targeting folate receptor (+) cells and scramble miRNA

 1nmol RNP-Msc-05-1
50nmol RNP-Msc-05-2
3WJ-RFC(GL)-Scr

Serum stable 3WJ RNA Nanoparticle with a galactose ligand for targeting liver cancer cells and scramble miRNA

 1nmol RNP-Msc-06-1
50nmol RNP-Msc-06-2
3WJ-RFM-Scr

Serum stable 3WJ RNA Nanoparticle with a mutant aptamer (serving as a targeting control) and scramble miRNA

 1nmol RNP-Msc-07-1
50nmol RNP-Msc-07-2
3WJ-RF-Scr

Serum stable 3WJ RNA Nanoparticle without ligand (serving as vector control) but with scramble miRNA

 1nmol RNP-Msc-08-1
50nmol RNP-Msc-08-2

RNA Nanoparticles for siRNA Delivery Study: Get Quote

Product Name Size Catalog No.
3WJ-RFC(FA)-siBRCAA1

Serum stable 3WJ RNA Nanoparticle with a folate ligand for targeting folate receptor (+) cells and BRCAA1 siRNA

 1nmol
RNP-Si-01-1
50nmol RNP-Si-01-2
3WJ-RFC(FA)-siScramble

Serum stable 3WJ RNA Nanoparticle with a folate ligand for targeting folate receptor (+) cells and scramble siRNA sequence

 1nmol RNP-Si-02-1
50nmol RNP-Si-02-2
3WJ-RF-siBRCAA1

Serum stable 3WJ RNA Nanoparticle without ligand (serving as vector control) with  an with BRCAA1 siRNA

 1nmol RNP-Si-03-1
50nmol RNP-Si-03-2

Copyright © Nanobio Delivery Pharmaceutical Co., Ltd. All rights reserved.